Drug intelligence / Profile preview

18F-1799

Development stage: Preclinical
Lead developer: Fuwai Hospital
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics

Overview

18F-1799 is a novel sympathetic nerve imaging tracer used in Positron Emission Tomography (PET) for cardiac sympathetic imaging. It is currently being investigated for its role in the prognostic evaluation of patients with heart failure and for understanding its relationship with arrhythmia in patients with hypertrophic cardiomyopathy.

Beyond the preview

Go deeper on 18F-1799.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 18F-1799.

Explore the full profile